Phase 2 clinical trial for OXE103 for the treatment of concussion is being conducted at University of Kansas Medical Center, Kansas City, Kansas Enrolling highly […]
Stimulating bitter taste receptors, the body’s early warning system for toxic substances, can fight obesity and inflammation. By Gail Dutton – February 02, 2022 Bitter […]
Two studies evaluate ARD-101 in Obesity: one in General Obesity and the other in Refractory Weight Gain Post-Bariatric Surgery. The 3rd clinical trial is in […]
Boston, MA, January 20, 2022 – Oxeia Biopharmaceuticals, a clinical stage biotech company conducting Phase 2 clinical trials of OXE103 for treating concussion, today announced […]